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Human telomerase reverse transcriptase (hTERT) is expressed in
most cancer cells. Paradoxically, its promoter is embedded in
a hypermethylated CpG island. A short region escapes to this
alteration, allowing a basal level of transcription. However, the
methylation of adjacent regions may play a role in the mainte-
nance of low hTERT expression. It is now well established that
methyl-CpG binding domain proteins mediate the transcriptional
silencing of hypermethylated genes. The potential involvement of
these proteins in the control of hTERT expression was firstly in-
vestigated in HeLa cells. Chromatin immunoprecipitation assays
showed that only methyl-CpG-binding domain protein 2 (MBD2)
associated the hypermethylated hTERT promoter. InMBD2 knock-
down HeLa cells, constitutively depleted in MBD2, neither methyl
CpG binding protein 2 (MeCP2) nor MBD1 acted as substitutes for
MBD2. MBD2 depletion by transient or constitutive RNA interfer-
ence led to an upregulation of hTERT transcription that can be
downregulated by expressing mouse Mbd2 protein. Our results
indicate that MBD2 is specifically and directly involved in the tran-
scriptional repression of hTERT in HeLa cells. This specific tran-
scriptional repression was also observed in breast, liver and
neuroblastoma cancer cell lines. Thus, MBD2 seems to be a general
repressor of hTERT in hTERT-methylated telomerase-positive cells.
Introduction
An increasing body of evidences indicate that the alterations of DNA
methylation patterns are a characteristic of cancer cells (1). Generally,
global reduction of DNA methylation level is associated with localized
hypermethylation (1). Specifically, an aberrant hypermethylation of
CpG islands at the 5# end of tumor suppressor genes, leading to tran-
scriptional repression, has been described both in cancer cell lines and
tumor tissues (2,3).
In human epithelial and fibroblast cells, telomere shortening is
a key event in replicative senescence. In .85% of cancer cells, telo-
mere length is maintained through telomerase holoenzyme activity
(4,5). Although germ cells and stem cells also exhibit high telomerase
activity (4), in normal somatic cells, the catalytic subunit of the telo-
merase [human telomerase reverse transcriptase (hTERT)] is si-
lenced, leading to a limited life span (6). The regulation of hTERT
transcription has been extensively investigated and several inductors
and repressors have been identified, including c-Myc, Sp1, hALP, Hif-1,
Mbi-1, USF1/2, estrogen response element, p53, Mad1, myeloid-
specific zinc finger protein 2, transforming growth factor-b, Wilms’
Tumor 1 and CTCF (7–9). In addition, the hTERT promoter region is
embedded in a large CpG island spanning nucleotides (nt) 1100 to
þ1500 from the transcription start site, suggesting that transcription
of the gene might be regulated by DNA methylation.
The first studies examining the methylation status of the hTERT CpG
island had led to a paradox. In normal somatic cells, this CpG island
was found unmethylated while the gene was transcriptionally silent.
However, in most of cancer cells, this region was aberrantly methylated,
whereas telomerase activities and hTERT messenger RNAs (mRNAs)
were unambiguously detected (10–13). This paradox was recently
solved. hTERT methylation prevents the binding of negatively acting
transcription factors such as CTCF inhibitor (9), and a partial hypome-
thylation of the hTERT promoter region can result in some level of
transcriptional activity (14). In several cancer cell lines and tumor
tissues, careful analysis of hTERT methylation patterns has shown
that a short region of the CpG island (positions nt 165 to nt 80) is
unmethylated or slightly methylated despite highly methylated border
regions (14). This unmethylated region is located in the hTERT core
promoter (positions nt 279 to nt þ5) (15), and chromatin immuno-
precipitation (ChIP) assays have shown that active chromatin marks are
associated with this unmethylated region (16). Moreover, studies using
plasmid expression vectors and patch methylation techniques indicate
that the hTERT core promoter does not show any activity when all CpG
sites are methylated (17). In contrast, the selective demethylation of
a small region upstream the transcription start site significantly activates
the hTERT promoter in a reporter plasmid. Nevertheless, the activity of
the promoter under these conditions is significantly lower than when
using the unmethylated core promoter. In this condition, hTERT does
not provide a real exception to the general model of gene silencing by
promoter methylation and the hypermethylation around the unmethy-
lated region seems to play a major role in the reduction of hTERT
transcriptional activity. Indeed, in telomerase-positive cancer cells, only
0.2–6 mRNA molecules per cell can be detected (18,19), suggesting
that the transcriptional activity of the hTERT promoter is limited by
cellular factors since high transcription rates are induced when the
unmethylated promoter is used in plasmid expression vectors (14).
Transcriptional repression mediated by CpG methylation often in-
volves methyl-CpG-binding domain (MBD) proteins. The five MBD
proteins identified to date, methyl CpG binding protein 2 (MeCP2),
MBD1, MBD2, MBD3 and MBD4, share a highly conserved MBD.
With the exception of MBD4, which is primarily a thymine glycosy-
lase involved in DNA repair (20), all MBD proteins are involved in the
transcriptional repression mediated by DNA methylation. It has now
been well established that MeCP2, MBD1 and MBD2 bind to meth-
ylated DNA and recruit different histone deacetylase complexes and
histone methyl transferases, belonging to the chromatin remodeling
complexes that control chromatin compaction and induce gene silenc-
ing (21–23). MBD3 lacks a functional MBD but is an integral subunit
of histone deacetylase complex the Mi2–NuRD complex that is re-
cruited through MBD2 (24,25).
These data have prompted us to investigate whether MBD proteins
are involved in the repression of hTERT expression when hyperme-
thylated in telomerase-positive cells.
Materials and methods
Cell culture
Five human tumor cell lines, HeLa (cervical adenocarcinoma), MCF7 (breast
adenocarcinoma), HepG2 (hepatocellular carcinoma), LAN-1 (neuroblastoma)
and NCCIT (teratocarcinoma) and a normal human embryonic lung fibroblast
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cell line, MRC5, were used in this study. Cells were obtained from the American
Type Culture Collection (Rockville, MD), except for LAN-1, and grown in the
medium recommended at 37C in a humidified 5% CO2 atmosphere.
ChIP assays
ChIP was done as described previously (26). Cross-linked chromatin was im-
munoprecipitated using 15 ll of two different polyclonal anti-MBD2 antibodies
(kindly provided by Dr P.Wade and Dr E.Ballestar) or 20 ll of polyclonal anti-
MeCP2 (Upstate Biotechnology, Lake Placid, NY), anti-MBD1 (Abcam, Paris,
France) antibodies or anti-mouse IgG (Dakocytomation, Trappes, France).
Purified DNAs obtained from the input, unbound and bound fractions were
quantified by densitometry using the VersaFluorTM Fluorometer (Bio-rad, Ivry,
France) and RiboGreen reagent (Molecular Probes, Interchim, Montlucxon,
France).
Polymerase chain reaction (PCR) analysis was then performed to assess the
binding of MBD proteins to the hTERT core promoter. An equal quantity
(0.4 ng) of each DNA fraction was amplified by dose-dependent PCR (supple-
mentary Figure S1 is available at Carcinogenesis Online) using HotStar Taq
polymerase Kit (Qiagen, Courtaboeuf, France), 5% of dimethyl sulfoxide and
0.5 lM of primers spanning a region from nt296 to nt84 of hTERT (hTERT
ChIP, see supplementary Table S1 available at Carcinogenesis Online). The
thermal cycler program was 37 cycles of 94C for 30 s, 65C for 60 s and 72C
for 90s. PCR products were analyzed on a 2% agarose gel containing 1 lg/ml
ethidium bromide and were quantified by densitometry using a Fluor’s fluo-
rimeter and Quantity One software (Bio-rad).
ChIP-on-chip
For ChIP-on-chip analysis, the specific protein–DNA complexes were ob-
tained from independent immunoprecipitations using two different polyclonal
anti-MBD2 antibodies (kindly provided by Dr P.Wade and Dr E.Ballestar). The
ChIP DNAs from the input and bound fractions were amplified, labeled and
hybridized on microarrays by ProfileXpert service according to AffymetrixTM
protocols. Briefly, the ChIP DNA was amplified by ligation-mediated PCR. To
test for enrichment of MBD2-bound sites, PCR amplification of NBR2 (26) and
pS2 promoters was performed on each ChIP samples before and after ampli-
fication. The amplified DNAs were then labeled using the GeneChip WT
Double-Stranded DNA Terminal Labelling Kit and hybridized to the human
tiling arrays (Human Promoter 1.0R Arrays), which were then washed and
scanned. Raw data from the scans were analyzed using Affymetrix Tiling
Analysis Software and the results were viewed in Affymetrix’ Integrated
Genome Browser Software.
DNA methylation analysis
Bisulfite sequencing used to determine the CpG methylation pattern of hTERT
promoter and proximal exonic region was performed as described previously
(12,14). Briefly, bisulfite-modified genomic DNA was amplified by two primer
sets [P1, positions nt 442 to nt 219 (12) and P2, positions nt 206 to nt
þ108 (14)] to analyze a region from nt442 to ntþ108 from the transcription
start site of hTERT. PCR amplifications were accomplished using the master
mix (Promega, Madison, WI), with the following conditions: 40 cycles of 94C
for 30 s, 54C (P1) or 57C (P2) for 45 s and 72C for 50 s. DNA methylation
status was then established by a direct sequencing of PCR products or by
a sequencing of cloned PCR products. For the last procedure, PCR products
were cloned into the pGEM-T vector using the pGEM-T vector system II (Prom-
ega). After transformation of JM109 Escherichia coli competent cells (Promega),
plasmid DNA was extracted from clones with the QIAprep Spin Miniprep
Kit (Qiagen). Each clone was sequenced with the M13 forward primer
(5#-GTAAAACGACGGCCAG-3#), using a Big Dye Terminator Cycle Sequenc-
ing Kit and an ABI Prism 3100 sequencer (Applied Biosystems, Foster City, CA).
Transient transfection
siRNA duplexes for MBD2 (sense: 5#-GGAGGAAGUGUACCGAAAATT-3#
and antisense: 5#-UUUUCGGAUCACUUCCUCCTT-3#; Eurogentec, Seraing,
Belgium); non-specific small interfering RNA (siRNA) control (Eurogentec);
pRev-Mbd2 (kindly provided by Dr A.Bird) (26) and pGL3 basic (Promega)
were transfected in cell lines using lipofectamine 2000 (Invitrogen, Carlsbad,
CA) according to the manufacturer’s recommendations. Briefly, cells were
seeded at 2  105 cells per well in six-well plates and grown to 50–60%
confluence on the day of transfection. All transfections were done in Opti-
MEM medium (Invitrogen) with 625 nM of MBD2 siRNA or 1 lg of Mbd2
expression plasmid. Lipofectamine 2000 complexes were incubated for 4–5 h.
The medium was then removed and replaced with fresh medium. Cells were
grown and harvested at various time after the transfection.
RNA extraction and reverse transcription–PCR analysis
Total RNA was extracted from cells using the RNeasy Mini Kit (Qiagen). After
extraction, the integrity of total RNA was examined on a 1.2% agarose gel
containing 1 lg/ml ethidium bromide and quantified by densitometry using
a Fluor’s fluorimeter and Quantity One software (Bio-rad) by comparison with
serial dilutions of a standard RNA (Roche Molecular Biochemicals, Maylan,
France).
MBD2 mRNA was quantified by competitive quantitative reverse transcrip-
tion (RT)–PCR as described previously (27). hTERT mRNA levels were mon-
itored by relative RT–PCR using One Step RT–PCR kit (Qiagen) and 0.1 lg of
total RNA. Cycling parameters were 50C for 30 min followed by 95C for
15 min and then 32 cycles of 94C for 30 s, 55C for 60 s and 72C for 90 s.
hTERT transcripts were co-amplified with PBGD transcripts used as internal
controls (for primers hTERT RT–PCR and PBGD RT–PCR, see supplementary
Table S1 available at Carcinogenesis Online). PCR products were analyzed on
a 2% agarose gel containing 1 lg/ml ethidium bromide and quantified by
densitometry. The ratio between hTERT and PBGD signals was determined.
To quantify more precisely hTERT mRNA, real-time RT–PCR was also carried
out on a Rotorgene 6000 cycler (Corbett Research, Sydney, Australia) using
C. therm. Polymerase One-Step RT–PCR System (Roche Molecular Biochem-
icals, Maylan, France). Each reaction mixture included 50 ng of template RNA,
250 nM of FAM-labeled probe (see supplementary Table S1 available at
Carcinogenesis Online) and 500 nM of primers specific for hTERT (hTERT
RT–PCR Q, see supplementary Table S1 available at Carcinogenesis Online).
Cycling parameters were 60C for 30 min followed by 95C for 5 min and then
45 cycles at 95C for 15 s and 60C for 60 s. b-Actin mRNA levels were used to
normalize hTERT expression. The relative level of each mRNAwas calculated on
the basis of two standard curves using the relative quantification method.
Results
hTERT hypermethylated CpG island is selectively associated with
MBD2 in HeLa cells
To explore the potential involvement of MBD proteins in hTERT
regulation, we have chosen cervical cancer cell line HeLa, as a first
model. In these telomerase-positive tumor cells, as was shown in our
earlier studies, the hTERT core promoter is also regionally hyperme-
thylated (17) and might be a target of MBD proteins.
To address this issue, ChIP assays were performed using antibodies
directed against MeCP2, MBD1 and MBD2. As a control, the frac-
tions immunoprecipitated with a non-MBD protein-specific antibody
(anti-mouse IgG) were also analyzed. The relative amounts of hTERT
core promoter were determined by a dose-dependent PCR assay (sup-
plementary Figure S1 available at Carcinogenesis Online) using a con-
stant amount of DNA from each fractionation process: input, unbound
and bound fractions. Representative data from at least three indepen-
dent experiments are shown in Figure 1A. A strong enrichment in
hTERT promoter was observed in the fraction immunoprecipitated
by anti-MBD2 antibodies when compared with input or non-retained
fractions (Figure 1A ‘input’, ‘unbound’ and ‘IgG’). Since dose-
dependent PCR assays were performed with a constant amount of
DNA, these data strongly suggest that MBD2 is associated with the
methylated region of the hTERT promoter. In contrast, analysis of the
fractions immunoprecipitated by anti-MeCP2 or anti-MBD1 antibod-
ies showed that these fractions were depleted in hTERT DNA (Figure
1A), indicating that these two proteins are not bound to hTERT pro-
moter in HeLa cells. Furthermore, the depletion in hTERT DNA ob-
served in the fractions bound by anti-MeCP2 and anti-MBD1
antibodies suggests that these two proteins are probably linked to
other chromatin domains in HeLa cells.
Taken together, these data strongly suggest that the methylated
regions adjacent to the unmethylated region of the hTERT core pro-
moter are selectively associated with MBD2.
Recently, we have developed high-throughput analyses of MBD2-
binding pattern using a ChIP-on-chip approach (A. Chatagnon,
L. Perriaud, J. Lachuer and R. Dante, in preparation). DNAs obtained
from the chromatin immunoprecipitated by anti-MBD2 antibodies
were hybridized to Affymetrix Human Promoter 1.0R Array. On this
chip, 25 500 human promoter regions tiled at 35 bp resolution are
representing. Each promoter region covers 7.5 kb upstream through
2.45 kb downstream of 5# transcription start site and for 1300 cancer-
associated genes, additional 2.45 kb are also represented. Data
obtained from two independent experiments performed with two dif-
ferent anti-MBD2 antibodies indicated that MBD2 not only bound the
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hypermethylated region of the hTERT core promoter but also covered
all the hypermethylated hTERT CpG island (Figure 2A). As a control,
results obtained for a previously identified MBD2-free hypermethy-
lated promoter (28), PARVG, are also shown on Figure 2B. As ex-
pected, no MBD2-positive signal was observed along this
hypermethylated promoter (Figure 2B).
The hypermethylated hTERT promoter remains free of MBD proteins
in MBD2-depleted cells
In HeLa cells, among the MBD transcripts, MBD2 mRNAs are the
most abundant (27), suggesting that the selective binding of MBD2 to
hTERT promoter might be due to its prominent expression. Thus, we
investigated hTERT promoter occupancy in a HeLa clone cell line
[MBD2 knockdown (KD) HeLa cells] constitutively depleted in
MBD2 by a transgene expressing a siRNA targeting the mRNA cod-
ing for this protein (26).
Quantitative competitive RT–PCR assays indicated that 89–96%
MBD2 mRNA depletion was obtained and maintained over many
passages in MBD2 KD HeLa cells. This low level of MBD2 transcripts
was correlated with a very low level of MBD2 protein, which was
almost undetectable in western blot experiments (26). In addition,
neither the amounts of MeCP2 and MBD1 transcripts nor the amounts
of the corresponding proteins were altered by MBD2 depletion (data
not shown).
As MBD2 belongs to the DNA methylation machinery, a prolonged
MBD2 depletion might alter DNA methylation patterns. Therefore, the
DNA methylation patterns of the hTERT promoter were determined in
MBD2 KD HeLa cells. DNA extracted from the cell lines was modified
and amplified by PCR with primers specifically designed to amplify
bisulfite-modified DNA sequence of the hTERT promoter and proximal
exonic region. PCR fragments were cloned and sequenced. The anal-
ysis of 10 clones from wild-type HeLa cells and MBD2 KD HeLa cells
indicated that over the hypermethylated hTERT promoter and proximal
exonic region, a small sequence (positions nt 165 to nt 80), corre-
sponding to a part of the hTERT core promoter, was hypomethylated in
the two cell lines analyzed (Figure 1B). Indeed, this region exhibit
a low level of methylation (30%) but no significant difference was
observed between wild-type HeLa cells and HeLa cells depleted in
MBD2. Thus, the methylation patterns of the hTERT promoter in
MBD2 KD HeLa cells were not altered by the absence of MBD2.
As expected, in HeLa cells depleted in MBD2 proteins, ChIP assays
indicated that MBD2 was no longer detected at the hypermethylated
region of the hTERT core promoter (Figure 1C). Furthermore, this
region seemed to remain free of MBD proteins since the immunopre-
cipitated fractions are depleted in the methylated hTERT promoter
when anti-MeCP2 or anti-MBD1 antibodies were used in ChIP ex-
periments (Figure 1C).
Thus, the hypermethylated region of the hTERT promoter is specif-
ically targeted by MBD2 in HeLa cells and no redundancy between
MBD2 and MeCP2 or MBD1 was observed at this hypermethylated
region.
MBD2 depletion enhances hTERT gene transcription in HeLa cells
MBD2 is a member of the MBD protein family and their methylation-
dependent repressive activities are now well established (29). There-
fore, we investigated the potential involvement of MBD2 in the
repression of the endogenous hTERT promoter in HeLa cells.
First, we determined the consequence of a transient MBD2 depletion
on the expression of hTERT in HeLa cells. At 24 h intervals after
MBD2-specific siRNA transfection, RNA was extracted and the levels
of hTERT and MBD2 transcripts determined by RT–PCR assays were
compared with their levels in HeLa cells transfected with a non-specific
siRNA. Quantitative competitive RT–PCR assays (27) indicated that
a reduction of 90% in MBD2 mRNA level was reached 24 h after
transfection with MBD2 siRNA and maintained .96 h after transfec-
tion (Figure 3A). Western blot analysis also showed a dramatic de-
crease in MBD2 proteins in these cells (data not shown). In HeLa
cells, 48 h after the MBD2 siRNA transfection, an elevation of 1.2-fold
of hTERT mRNA level was observed when compared with HeLa cells
transfected with a non-specific siRNA. This stimulation increased to
a maximum of 1.9 at 96 h after MBD2 siRNA treatment. The expres-
sion level of hTERT was determined using relative RT–PCR (Figure
3A) and identical results were obtained with real-time RT–PCR for
critical points (Figure 3B). It should be noted that neither the level of
MBD2 transcripts nor the level of hTERT transcripts were altered by
non-specific siRNA transfection when compared with untreated wild-
type HeLa cells (data not shown).
These data suggest that MBD2 actually represses hTERT expres-
sion in HeLa cells.
Stimulation of hTERT transcription in MBD2 KD HeLa cells is
reversed by ectopic expression of Mbd2
The MBD2 KD HeLa cell line offers the opportunity to investigate the
functional control of the specific repression of hTERT by MBD2. In this
cell line, MBD2 expression can be rescued using pRev-Mbd2, a vector
coding for a mouse Mbd2 RNA containing five silent point mutations
and, therefore, refractory to siRNA-mediated decay (26). We also ob-
served a 2-fold stimulation of hTERT expression in the MBD2 KD
HeLa cells as compared with wild-type HeLa cells (Figure 4). In these
Fig. 1. MBD2 specifically binds the hypermethylated region of the hTERT
promoter in HeLa cells. (A) ChIP analysis of MBD proteins binding to the
hypermethylated region of the hTERT promoter (positions nt296 to nt84
from the ATG translational start site) in HeLa cells. Cross-linked chromatin
was immunoprecipitated using anti-MeCP2, anti-MBD1 and anti-MBD2
antibodies or anti-mouse IgG. The relative amounts of hTERT core promoter
were determined by a dose-dependent PCR assay using a constant amount of
DNA from each step of the fractionation process: input, unbound and bound
fractions. The intensities of the bands corresponding to representative PCR
products amplified from the input, unbound and bound fractions are shown.
(B) Genomic bisulfite sequencing profiles of hTERT promoter and proximal
exonic region in wild-type HeLa and MBD2 KD HeLa cells. A 550 bp region
(positions nt 442 to nt þ108) of the hTERT CpG island is presented on
a schematic map. White dotted box, core promoter; black arrows,
transcription start sites. Bisulfite-sequencing status of hTERT promoter and
proximal exonic region is shown (number of analyzed clones for each cell
line, n 5 10). Each line represents a single-DNA template molecule. Filled
and open squares, respectively, represent methylated and unmethylated
CpGs. Sequencing was performed from two different regions that do not
overlap (see Materials and Methods), leading to unanalyzed CpGs, barred
squares. The slightly methylated region (positions nt 165 to nt 80) is
framed. (C) MeCP2 and MBD1 do not compensate for MBD2 depletion at
the hTERT promoter in MBD2 KD HeLa cells. Representative examples of
ChIP assays performed in MBD2 KD HeLa cells are presented.
A.Chatagnon et al.
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cells, the ectopic expression of Mbd2 reduced hTERT transcription to
a level similar to the level observed in wild-type HeLa cells (Figure 4),
suggesting that MBD2 directly represses hTERT expression in HeLa
cells. In wild-type HeLa cells, the abundance of MBD2 does not seem
to be a limiting factor since the overexpression of MBD2 mediated by
pRev-Mbd2 transfection did not modify hTERTexpression level in cells
containing normal amounts of MBD2 (Figure 4).
Our results demonstrate that MBD2 specifically binds to hTERT
and represses its expression in HeLa cells.
MBD2 hTERT repression is specifically observed in hTERT-
methylated telomerase-positive cancer cell lines and independent of
the cellular types
Data obtained suggest that MBD2 might be a general repressor of
hTERT transcription in hTERT-methylated telomerase-positive cells.
In order to address this point, we tested whether the above-mentioned
MBD2 KD-mediated hTERT stimulation in HeLa cells could be re-
capitulated in other hTERT-methylated cell lines. A functional study
was undertaken in different cell lines exhibiting characteristic hTERT
DNA methylation patterns: (i) MCF-7, LAN-1 and HepG2 cells, three
telomerase-positive cancer cell lines showing an hTERT core pro-
moter unmethylated or slightly methylated despite an hypermethy-
lated CpG island (ii) NCCIT cells, an hTERT-unmethylated
telomerase-positive teratocarcinoma cell line and (iii) MRC5 cells,
an hTERT-unmethylated telomerase-negative normal embryonic cell
line. The hTERT core promoter methylation status of these cell lines
and the corresponding transcript levels are shown in Figure 5. Control
experiments indicated that these cell lines exhibited approximatively
the same level of MBD2 transcripts (4.8 ± 2.7  106 mRNA mole-
cules per microgram of total RNA), with the exception of NCCIT (7
104 mRNA molecules per microgram of total RNA).
As observed in HeLa cells, a significant decrease of MBD2 tran-
scripts (60–79%) was observed in the different cell lines 96 h after
MBD2 siRNA transfection. Relative to the transfection with a non-
specific siRNA, a 2-fold increase in hTERT mRNA was observed in
all hTERT-methylated cell lines, LAN-1, MCF7 and HepG2 cells. In
contrast, MBD2 depletion did not affect hTERT expression in hTERT-
unmethylated cell lines, NCCIT and MRC5 cells (Figure 6). Since
MBD2 does no bind to unmethylated DNA (24,25), these data in-
dicate that hTERT induction due to MBD2 depletion is not mediated
by an indirect effect.
Taken together, the specific transcriptional repression of hTERT by
MBD2 does not seem to be restricted to a particular cancer cell line
since this effect was observed in cervix, breast, liver and neuroblas-
toma cancer cell lines. Thus, MBD2 seems to be a general repressor of
hTERT in hTERT-methylated telomerase-positive cells.
Discussion
Most (96%) of the CpG islands are unmethylated in normal cells
(30), whereas hypermethylation of these sequences is a characteristic
Fig. 2. ChIP-on-chip analysis of MBD2-binding sites on hTERT promoter. (A) Array peaks on hTERT promoter of MBD2 log2 signal ratio (MBD2/input) values are
shown below the Affymetrix’ Integrated Genome Browser window. Gene is transcribed from right to left. hTERT CpG island is shown by a red box. DNA fragment
analyzed by PCR following MBD2 ChIP is represented by a white box. (B) PARVG 5# end viewed as a MBD2-free control. Gene is transcribed from left to right.
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of cancer cells (1). These aberrant DNA methylation patterns have
been correlated with the transcriptional silencing of genes undergoing
such alterations at their 5# end CpG islands. The hTERT gene has
provided an interesting exception since a bimodal alteration of the
DNA methylation status of its 5# end CpG island is associated with its
expression in85% of cancer cells and tumors tissues (4,5). The large
CpG island, 2.6 kb in length, lying from nt 1102 to nt þ1519 from
the hTERT transcription, is hypermethylated at the exception of a short
region (positions nt 165 to nt 80) that is unmethylated or slightly
methylated despite highly methylated border regions (16,17). This
particular pattern of methylation seems crucial for establishing
Fig. 3. Transient depletion of MBD2 proteins by MBD2-specific siRNA induces time-dependent stimulation of hTERT expression in HeLa cells. (A) HeLa cells
were transiently transfected, with either MBD2 siRNA or a negative control scrambled siRNA. After 24, 48, 72 or 96 h following the transfection, RNA was
extracted and the efficiency of the MBD2 siRNA treatment was determined by quantification of MBD2 mRNA as described previously (27). hTERT mRNA levels
were monitored by relative RT–PCR. The fold induction of hTERT expression was calculated from the ratio hTERT mRNA/PBGD mRNA in MBD2 siRNA-
transfected cells versus scrambled siRNA-transfected cells. Mean values (± standard deviation) obtained from at least three independent transfection experiments
are shown. Filled squares, MBD2 mRNA level; filled circles, fold induction of hTERT mRNA. (B) Quantitative RT–PCR expression analysis of hTERT in HeLa
cells 96 h after transfection with either a negative control siRNA or MBD2 siRNA. Real-time RT–PCR was done on cells lines and hTERT expression was
normalized to b-actin. The relative level of each mRNA was calculated on the basis of the two standard curves using the relative quantification method. At least
three independent determinations of fold differences were used to calculate the average fold difference values and associated standard deviation (P 5 0.0027;
t-test).
Fig. 4. Mbd2 expression rescues the reduction of hTERT transcript in MBD2
KD HeLa cells. The transcriptional expression of hTERT was analyzed by
quantitative RT–PCR 48 h after lipofectamine transfection of HeLa and
MBD2 KD HeLa cells using pRev-Mbd2, an Mbd2 vector expressing
a transcript resistant to RNAi or an empty pGL3 basic vector. The relative
hTERT mRNA in pRev-Mbd2-transfected cells or in pGL3-transfected cells
or in KD HeLa cells was calculated using the same reference: the hTERT
mRNA level in untransfected HeLa cells. Mean values obtained from at least
three independent transfection experiments are shown (P 5 0.0035, t-test).
Fig. 5. DNA methylation patterns of hTERT and the corresponding transcript
levels in different cell lines. (A) Bisulfite sequencing of five telomerase-
positive cancer cell lines (HeLa, MCF7, HepG2, LAN-1 and NCCIT) and
one normal telomerase-negative fibroblast cell line (MRC5). Bisulfite-treated
DNA was PCR amplified using a primer set spanning the end of the promoter
and the proximal exonic region of hTERT. PCR products were then directly
sequenced. The analyzed 314 bp region (206 to þ108) is presented on
a schematic map and results are shown for each cell lines. Filled and open
squares, respectively, represent complete methylated and unmethylated CpG
sites, whereas gray squares correspond to partial methylated CpG sites. (B)
Quantitative expression of hTERT in MRC5, NCCIT, HepG2, LAN-1, MCF7
and HeLa cells. Real-time RT–PCR was done on cell lines, and b-actin was
used as a reference.
A.Chatagnon et al.
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hTERT expression at a basal level. Indeed, hypermethylation of
CpG islands seems to be a crucial event in carcinogenesis. Thus,
the methylation-free region in hTERT promoter may result from
antagonistic pressure between the mechanisms leading to aberrant
methylation and the need to keep hTERT expressed for unlimited life
span of cancer cells.
A body of evidence has been accumulated concerning association
between hypermethylation of CpG islands, transcriptional silencing
and MBD-proteins binding (21). ChIP experiments and ChIP-on-chip
analysis indicate that MBD2 associated the hypermethylated CpG
island of hTERT. In this context, MBD2 seems to be a limiting factor
rather than a transcriptional silencer.
Recently, a large screening of tumor suppressor gene promoters
in 10 cell lines showed that human cancer cell lines tend to use a
particular MBD protein (31). Furthermore, in MRC5 cells, ChIP ex-
periments have indicated that MeCP2 and MBD2 proteins have non-
overlapping binding specificities in vivo (23). These data, as well as
our data are in favor of the ‘one gene–one MBD’ hypothesis, at least
for some genes. Indeed, MBD2 was specifically associated with the
methylated region of the hTERT CpG island, whereas MeCP2 and
MBD1 were not detected at this locus. Moreover, MBD2 depletion
did not induce MeCP2 or MBD1 binding at this methylated area in
HeLa cells. Thus, the specificity of MBD proteins does not seem to be
driven by their relative concentrations in a cell line, as it was sug-
gested in an other study (31): a strong expression of a particular MBD
is not necessarily associated with its preferential use in promoters.
Several studies have shown that transcriptional activation could be
realized upon depletion of MBD proteins by RNA interference
(RNAi) (26,28). A large-scale microarray analysis indicated that
15% of 6386 genes analyzed exhibit an increased expression change
between untreated and triple MBD-depleted cells (28). It should be
noted that for single-MBD interference, MBD2 depletion was the
protein most commonly involved in the observed release of gene
silencing by far (28). These data suggest that MBD2 plays an impor-
tant role in methylation-dependent gene silencing. MBD2 depletion
mediated by RNAi stimulates hTERT expression, either in stable KD
HeLa clones or in transiently transfected HeLa cells. A 2-fold stim-
ulation of hTERT expression upon MBD2 depletion was observed,
suggesting that MBD2 plays an important role in the regulation of
this gene. Indeed, in human cell lines, fold changes induced by MBD2
depletion is also of the same range, 2-fold for NBR2 induced by
MBD2 siRNA (26) and microarray analysis of MBD2-depleted cells
exhibited a mean fold change of 7 (28). Furthermore, the fold change
observed in Mbd2-deficient mouse cells is not very different from our
own data. For example, it has been shown (32) that Mbd2/ fibro-
blasts had 3-fold higher levels of Xist than wild-type cells. Moreover,
elevated hTERT transcription upon MBD2 depletion is not limited to
cervix (HeLa cells) since this effect was observed in breast, liver and
neuroblastoma cancer cell lines. MBD2 RNAi experiments in cell
lines exhibiting unmethylated hTERT CpG island (MRC5 and
NCCIT) did not affect hTERT transcription indicating that MBD2
specifically and directly represses hTERT expression in methylation-
dependent manner. Collectively, these data strongly suggest that
MBD2 is a general repressor of hTERT expression in cancer cells.
A considerable number of transcription factors have been proposed
as negative regulators of hTERT transcription. Nevertheless, direct
evidence indicating that hTERT gene transcription is downregulated
remains to be firmly established. Thus, MBD2 may represent a new
factor directly involved in the negative regulation of hTERT expres-
sion. In cancer cells, MBD2 seems to play a specific role since its
binding to the hypermethylated part of the hTERT promoter estab-
lishes a direct link between a common DNA alteration of tumor cells,
CpG hypermethylation and a reduced level of hTERT transcription.
The binding of MBD2 represents an additional layer for the control of
hTERT expression, thereby underlying the importance of hTERT reg-
ulation in immortalized and cancers cells.
Supplementary material
Supplementary Figure S1 and Table S1 can be found at http://carcin.
oxfordjournals.org/
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